This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The FDA approved BridgeBio s first drug, for a disease that affects 100 children in the US and Europe.
BridgeBio mitigates risk with a hub-and-spoke model, with a central management team and subsidiaries.
The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says.
It wasn t that long ago that the idea behind BridgeBio drew laughter from biotech and finance experts.
But these days, CEO Neil Kumar says he s taking calls from industry insiders interested in launching companies emulating the BridgeBio model. If it helps patients, he s willing to guide rivals.
Posted on 354
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. Total revenues for the full year of 2020 were $6,069.9 million, a 22 percent increase compared to the same period in 2019. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $52.0 million, inclusive of hedging activities. On a GAAP basis, diluted EPS for the full year of 2020 was $2.72, compared to $10.70 in the prior year. Full year 2020 includes impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset and a related deferred tax benefit of $377.3 million. Full year 2019 includes one-time tax benefits of $382.2 million related to intra-entity asset transfers of intellectual property. Non-GAAP diluted EPS for the full year of 2020 was $12.51, a 19 percent increase versus the prior year.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. .
AKAMPIONJanuary 19, 2021 GMT
San Francisco, CA / Berlin, Germany – January 19, 2021 T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
“We welcome Tom and Camille to T-knife and look forward to their contributions as we continue to build our best-in-class T-cell receptor platform, advance our pipeline of innovative cell therapies, and transition to becoming a clinical-stage company in 2021,” stated Alexander Mayweg, Ph.D
Eidos Therapeutics, Inc. (NASDAQ: EIDX)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Eidos Therapeutics, Inc. (NASDAQ: EIDX) in connection with the proposed interested-party acquisition of the company by BridgeBio Pharma, Inc. ( BridgeBio ). Under the terms of the agreement, EIDX shareholders can elect to receive either 1.85 shares of BridgeBio or $73.26 for each share of EIDX share they own, subject to proration such that the aggregate cash portion will not exceed $175 million. If you own EIDX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/eidx/